The glucagon-like peptide-1 receptor (GLP-1R) is a class B GPCR that has proved to be an effective therapeutic target as several peptide-based agonists have been developed and registered for treating type 2 diabetes mellitus (13, 14). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.